Genomics BioSci & Tech. Co.,Ltd. (TPEX:4195)
Taiwan
· Delayed Price · Currency is TWD 29.40
-0.60 (-2.00%)
Apr 29, 2026, 1:54 PM CST
Genomics BioSci & Tech. Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | -39.43 | -223.1 | -168.07 | 71.6 | 18.74 | Upgrade
|
| Depreciation & Amortization | 73.47 | 62.51 | 39.37 | 32.52 | 33.23 | Upgrade
|
| Other Amortization | 2.31 | 0.85 | 0.61 | 0.46 | 0.73 | Upgrade
|
| Loss (Gain) From Sale of Assets | -2.89 | 2.42 | - | - | -65.18 | Upgrade
|
| Loss (Gain) From Sale of Investments | -25.14 | 47.06 | 65.29 | -124.76 | 9.31 | Upgrade
|
| Loss (Gain) on Equity Investments | - | 52.72 | 19.56 | 18.88 | 13.46 | Upgrade
|
| Stock-Based Compensation | - | 0.01 | 0.63 | 0.91 | - | Upgrade
|
| Provision & Write-off of Bad Debts | 9.54 | 1.44 | -3.09 | 1.86 | -0.57 | Upgrade
|
| Other Operating Activities | -27.67 | -5.74 | 3.29 | 0.19 | -4.87 | Upgrade
|
| Change in Accounts Receivable | -52.49 | -20.86 | -0.78 | -20.16 | -6.61 | Upgrade
|
| Change in Inventory | -52.76 | -132.8 | -10.82 | -20.58 | 1.84 | Upgrade
|
| Change in Accounts Payable | 31.34 | 64.48 | -10.73 | 13.05 | -0.51 | Upgrade
|
| Change in Unearned Revenue | -10.26 | 30.97 | -7.28 | 1.11 | 7.15 | Upgrade
|
| Change in Other Net Operating Assets | 7.19 | 8.26 | -24 | 3.81 | -34.48 | Upgrade
|
| Operating Cash Flow | -86.79 | -111.77 | -96.02 | -21.13 | -27.76 | Upgrade
|
| Capital Expenditures | -73.49 | -193.62 | -150.26 | -94.08 | -93.59 | Upgrade
|
| Sale of Property, Plant & Equipment | 8.07 | - | - | - | 7.93 | Upgrade
|
| Divestitures | - | - | - | - | -134.84 | Upgrade
|
| Sale (Purchase) of Intangibles | -3.08 | -3.58 | -1.11 | -0.15 | -1.23 | Upgrade
|
| Investment in Securities | 12.53 | -95.29 | -7 | 123.47 | -40.42 | Upgrade
|
| Other Investing Activities | -12.53 | -2.02 | 0.63 | -0.41 | -55.49 | Upgrade
|
| Investing Cash Flow | -67.84 | -293.92 | -157.74 | 28.83 | -317.64 | Upgrade
|
| Short-Term Debt Issued | 357.09 | 128.96 | 50 | 50 | - | Upgrade
|
| Long-Term Debt Issued | 40 | 152.48 | 147.08 | 90 | 35.02 | Upgrade
|
| Total Debt Issued | 397.09 | 281.44 | 197.08 | 140 | 35.02 | Upgrade
|
| Short-Term Debt Repaid | -235.95 | -50 | -50 | - | -50 | Upgrade
|
| Long-Term Debt Repaid | -49.4 | -15.72 | -100.32 | -8.16 | -7.2 | Upgrade
|
| Total Debt Repaid | -285.34 | -65.72 | -150.32 | -8.16 | -57.2 | Upgrade
|
| Net Debt Issued (Repaid) | 111.75 | 215.73 | 46.76 | 131.84 | -22.18 | Upgrade
|
| Issuance of Common Stock | 9 | - | 150.4 | 65.52 | - | Upgrade
|
| Common Dividends Paid | - | - | -7.1 | -0 | -0.04 | Upgrade
|
| Other Financing Activities | 0.01 | 108.68 | - | - | 0.08 | Upgrade
|
| Financing Cash Flow | 120.75 | 324.41 | 190.06 | 197.35 | -22.13 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.41 | 0.83 | -0.27 | 4.46 | -1.92 | Upgrade
|
| Net Cash Flow | -34.29 | -80.45 | -63.97 | 209.51 | -369.45 | Upgrade
|
| Free Cash Flow | -160.28 | -305.39 | -246.28 | -115.21 | -121.35 | Upgrade
|
| Free Cash Flow Margin | -22.63% | -59.00% | -62.17% | -27.50% | -31.12% | Upgrade
|
| Free Cash Flow Per Share | -2.21 | -4.21 | -3.46 | -1.81 | -2.01 | Upgrade
|
| Cash Interest Paid | 14.85 | 9.7 | 4.79 | 1.98 | 1.67 | Upgrade
|
| Cash Income Tax Paid | -0.02 | 0.15 | 0.81 | 0.01 | - | Upgrade
|
| Levered Free Cash Flow | -146.96 | -257.92 | -219.64 | -104.84 | -123.73 | Upgrade
|
| Unlevered Free Cash Flow | -138.4 | -253.08 | -216.68 | -103.6 | -122.68 | Upgrade
|
| Change in Working Capital | -76.98 | -49.95 | -53.61 | -22.77 | -32.61 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.